Skip to main content
Cidara Therapeutics, Inc. logo

Cidara Therapeutics, Inc. — Investor Relations & Filings

Ticker · CDTX ISIN · US1717572069 LEI · 549300IHQ9Z7RI1X2D22 US Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2021-01-25 Director's Dealing
Country US United States of America
Listing US CDTX

About Cidara Therapeutics, Inc.

https://www.cidara.com/

Cidara Therapeutics, Inc. is a biotechnology company that develops targeted immunotherapies and novel anti-infectives for patients with serious diseases. The company utilizes its proprietary Cloudbreak® platform to create drug-Fc conjugates (DFCs). These DFCs are engineered as 'single molecule cocktails' by coupling targeted small molecules or peptides to a human antibody fragment (Fc). This approach is designed to directly inhibit disease targets, such as fungal or viral pathogens, while simultaneously engaging the patient's immune system. The company's focus is on developing therapies for the treatment and prevention of life-threatening infections and other serious conditions.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2021-01-25 English
FORM 3 SUBMISSION
Director's Dealing
2021-01-25 English
FORM 4 SUBMISSION
Director's Dealing
2021-01-25 English
FORM 3 SUBMISSION
Director's Dealing
2021-01-25 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated January 22, 2021, reporting changes in the company's board of directors. It announces the increase in board size and the appointment of two new directors, including their committee assignments and compensation. There is no financial data or earnings information, nor is it a report or presentation. The content clearly fits the category of announcements related to changes in board or senior management. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is about 4900 characters, which is sufficient for a detailed announcement rather than a brief notice or report publication announcement.
2021-01-25 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated December 7, 2020, by Cidara Therapeutics, Inc. It announces the adoption of a new Inducement Incentive Plan by the Board of Directors. The content focuses on a corporate governance action related to stock incentive plans and includes exhibits of the plan and related agreements. The document is relatively short (4506 characters) and is a regulatory filing reporting a corporate event rather than a full financial report or detailed management discussion. It does not contain financial statements or earnings data, nor is it a proxy or voting result announcement. The primary purpose is to inform about a board action and related plan adoption, which fits best under Regulatory Filings (RNS) as a general SEC filing that does not fit other specific categories.
2020-12-07 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.